SCISPARC
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
SCISPARC
Industry:
Biotechnology Cannabis Medical
Founded:
2014-01-01
Address:
Giv'atayim, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.therapixbio.com
Total Employee:
11+
Status:
Active
Contact:
97236167055
Email Addresses:
[email protected]
Total Funding:
18.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS CPanel SSL CPanel
Similar Organizations
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-31 | MitoCareX Bio Ltd | SciSparc investment in Venture Round - MitoCareX Bio Ltd | 700 K USD |
| 2014-04-02 | LaraPharm | SciSparc investment in Venture Round - LaraPharm | 1.5 M USD |
Official Site Inspections
http://www.therapixbio.com
- Host name: 241.206.interhost.net
- IP address: 185.18.206.241
- Location: Israel
- Latitude: 31.5
- Longitude: 34.75
- Timezone: Asia/Jerusalem
More informations about "SciSparc"
SciSparc - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 97236167055 SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced …See details»
Therapix Biosciences Ltd. | LinkedIn
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists.See details»
Therapix Biosciences Ltd. - Company Profile & Staff Directory
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and …See details»
Therapix Biosciences Announces Name Change to SciSparc Ltd.
TEL AVIV, Israel, Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based …See details»
FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences
Oct 22, 2018 Please visit our website for more information at www.Therapixbio.com. ... Organization Profile. FSD Pharma Inc. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET …See details»
Therapix Biosciences and Cyntar Ventures Entered a Non
TEL AVIV, Israel, Jan. 5, 2021 /PRNewswire/ -- Therapix Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based …See details»
Therapix Biosciences - Craft
Jan 28, 2021 Therapix Biosciences (formerly NasVax) is a specialty clinical-stage company that focuses on cannabinoid pharmaceuticals. It develops a range of drug candidates for the …See details»
Therapix Biosciences - VentureRadar
Website: https://therapixbio.com. Develops cannabinoid-based pharmaceuticals for treatment of Tourette syndrome, obstructive sleep apnea, pain, autism spectrum disorder, and epilepsy …See details»
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding …
Jan 5, 2021 Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada Therapix's TheraPEA product has all required …See details»
Therapix Biosciences Announces Name Change to SciSparc Ltd.
TEL AVIV, Israel, Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based …See details»
Therapix Biosciences Signs LOI to Merge With Destiny Biosciences …
TEL AVIV, Israel, July 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on …See details»
Therapix Biosciences Announces Canadian Product License
Jul 31, 2019 Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the World Health Organization, half of the most prevalent conditions responsible …See details»
FSD Pharma Signs Binding LOI to Acquire Therapix ... - Business Wire
Oct 22, 2018 FSD Pharma Inc. Zeeshan Saeed, (416) 854-8884 Executive Vice President, Co-Founder and Director [email protected] or Investor Relations [email protected] …See details»
Therapix Biosciences Announces Canadian Product License …
Jul 31, 2019 About Destiny Biosciences Destiny Bioscience Global Corp is a science-based cannabis genetics and tissue culture research and development company, based in …See details»
Therapix Biosciences Announces Canadian Product License …
Jul 31, 2019 Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the World Health Organization, half of the most prevalent conditions responsible …See details»
Therapix Biosciences Initiates Non-clinical Studies for its ...
Oct 30, 2017 According to the World Health Organization, antimicrobial resistance, classified as a 'serious threat', occurs when microorganisms are exposed to antimicrobial drugs. As a …See details»
Therapix Biosciences to Collaborate with The University of Calgary …
Dec 2, 2020 Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain "In the era of America's deadly …See details»
Therapix Biosciences Announces Pricing of $4.2 Million Offering
Nov 19, 2020 Please visit our website for more information at www.therapixbio.com, the content of which is not a part of this press release. Investor Contact: Oz Adler, CFO [email protected]See details»
Therapix Biosciences Signs Binding LOI to be Acquired by FSD
Oct 24, 2018 Please visit our website for more information at www.therapixbio.com About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9): FSD Pharma through its wholly-owned …See details»